Natera (NTRA): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Natera’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$14,957,319CEO Steven Chapman · source

Say-on-pay support97.96%Latest vote · source

CEO vs. named peers53rd pct.Of 18 peer CEOs

CEO pay ratio101:1To the median employee · source

CEO pay, last three years

$12,727,887FY2023
$13,032,674FY2024
$14,957,319FY2025

CEO total pay was $14,957,319 in fiscal 2025, up from $13,032,674 in fiscal 2024.

FY2025: salary $853,710 · bonus $0 · stock awards $12,979,558 · option awards $0

Executives and directors

Matthew Rabinowitz · Executive Chairman Michael Brophy · CFO Solomon Moshkevich · President Steven Chapman · CEO John Fesko · President Gail Marcus · Independent Director Herm Rosenman · Independent Director James Healy · Independent Director Jonathan Sheena · Director Monica Bertagnolli · Independent Director Roelof Botha · Lead Independent Director Rowan Chapman · Independent Director Roy Baynes · Independent Director Ruth Williams-Brinkley · Independent Director

Frequently asked questions

Who was the highest-paid executive at Natera in fiscal 2025?

As disclosed, Steven Chapman (Chief Executive Officer, President and Director) was the highest-paid executive at Natera in fiscal 2025, with total compensation of $14,957,319.

How does Natera's chief executive pay compare to its disclosed peer group?

As disclosed, Steven Chapman's total compensation ranked at the 53rd percentile of Natera's disclosed peer group.

What is Natera's CEO-to-median employee pay ratio?

As disclosed, Natera's CEO-to-median employee pay ratio was 101:1.

How did shareholders vote on Natera's executive compensation?

As disclosed, 97.96% of shareholders supported Natera's executive compensation in the latest say-on-pay vote.

How much does Natera spend in total on board compensation for fiscal 2025?

As disclosed, Natera reported total board compensation of $3,350,663 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Steven Chapman	$853,710	$0	$12,979,558	$0	$1,114,151	$0	$9,900	$14,957,319
Chief Executive Officer, President and Director
Matthew Rabinowitz	426,434	0	10,383,434	0	473,514	0	0	11,283,382
Executive Chairman
Michael Brophy	562,794	0	4,500,844	0	390,175	0	6,209	5,460,022
Chief Financial Officer
Solomon Moshkevich	504,652	0	4,500,844	0	351,604	0	9,900	5,367,000
President, Clinical Diagnostics
John Fesko	504,652	0	4,186,634	0	351,604	0	9,900	5,052,790
President, Chief Business Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Steven Chapman	$14,957,319	$13,032,674	$12,727,887	↑ +1,924,645
Matthew Rabinowitz	11,283,382	9,834,129	8,968,366	↑ +1,449,253
Michael Brophy	5,460,022	4,887,334	5,069,225	↑ +572,688
Solomon Moshkevich	5,367,000	4,888,856	—	↑ +478,144
John Fesko	5,052,790	4,888,856	—	↑ +163,934

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The primary objectives of our executive compensation program are to: Reward the achievement of specified performance goals (pay for performance); Align our executive officers interests with those of our stockholders through long-term incentives linked to revenue growth and enhancement of stockholder value that also facilitate executive retention; Attract, retain and motivate superior executive talent with market competitive compensation

CEO STI target (% of salary)	100%
CEO LTI target (% of salary)	—
Independent consultant	Aon
Clawback policy	true
Anti-hedging	true
Anti-pledging	True

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Steven Chapman	RSU	2025-01-31	—	—	36,682	—	$6,489,779
Steven Chapman	PSU	2025-01-31	18,341	36,682	—	73,364	6,489,779
Solomon Moshkevich	RSU	2025-01-31	—	—	12,720	—	2,250,422
Matthew Rabinowitz	PSU	2025-01-31	14,673	29,345	—	58,690	5,191,717
Michael Brophy	PSU	2025-01-31	6,360	12,720	—	25,440	2,250,422
John Fesko	PSU	2025-01-31	5,916	11,832	—	23,664	2,093,317
Solomon Moshkevich	PSU	2025-01-31	6,360	12,720	—	25,440	2,250,422
John Fesko	RSU	2025-01-31	—	—	11,832	—	2,093,317
Matthew Rabinowitz	RSU	2025-01-31	—	—	29,345	—	5,191,717
Michael Brophy	RSU	2025-01-31	—	—	12,720	—	2,250,422

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Steven Chapman	$6,489,779	$6,489,779	$0	50.0%
Solomon Moshkevich	2,250,422	2,250,422	0	50.0%
Matthew Rabinowitz	5,191,717	5,191,717	0	50.0%
Michael Brophy	2,250,422	2,250,422	0	50.0%
John Fesko	2,093,317	2,093,317	0	50.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Solomon Moshkevich	RSU	571	—	$130,810
John Fesko	RSU	856	—	196,101
Michael Brophy	RSU	1,522	—	348,675
Matthew Rabinowitz	Option	2,292	65.47	—
Solomon Moshkevich	RSU	3,206	—	734,463
Chapman	RSU	3,386	—	775,699
John Fesko	RSU	3,607	—	826,328
John Fesko	RSU	11,640	—	2,666,608
Solomon Moshkevich	RSU	11,640	—	2,666,608
John Fesko	RSU	11,832	—	2,710,593
John Fesko	PSU	11,832	—	2,710,593
Michael Brophy	RSU	12,720	—	2,914,025
Michael Brophy	PSU	12,720	—	2,914,025
Solomon Moshkevich	RSU	12,720	—	2,914,025
Solomon Moshkevich	PSU	12,720	—	2,914,025
Michael Brophy	RSU	15,520	—	3,555,477
Michael Brophy	RSU	17,636	—	4,040,231
John Fesko	RSU	17,636	—	4,040,231
Solomon Moshkevich	RSU	17,636	—	4,040,231
Matthew Rabinowitz	RSU	29,345	—	6,722,646
Matthew Rabinowitz	PSU	29,345	—	6,722,646
Solomon Moshkevich	RSU	29,423	—	6,740,515
Michael Brophy	PSU	31,352	—	7,182,430
John Fesko	PSU	31,352	—	7,182,430
Solomon Moshkevich	PSU	31,352	—	7,182,430
Chapman	RSU	36,682	—	8,403,479
Chapman	PSU	36,682	—	8,403,479
Matthew Rabinowitz	RSU	38,799	—	8,888,463
Chapman	RSU	39,771	—	9,111,138
John Fesko	PSU	40,000	—	9,163,600
Matthew Rabinowitz	Option	41,342	43.74	—
John Fesko	RSU	44,698	—	10,239,865
Solomon Moshkevich	RSU	44,698	—	10,239,865
Chapman	RSU	48,499	—	11,110,636
Michael Brophy	RSU	59,598	—	13,653,306
Matthew Rabinowitz	PSU	68,976	—	15,801,712
Chapman	PSU	86,220	—	19,752,140
Chapman	RSU	152,718	—	34,986,167

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Roelof BothaIndependent · Lead Independent Director · Nominating, Corporate Governance and Compliance Committee	$28,451	$485,013	$0	$0	—	$513,465
Herm RosenmanIndependent · Audit Committee (Chair) · Human Capital Committee	25,222	475,849	0	0	0	501,070
Rowan ChapmanIndependent · Audit Committee · Human Capital Committee (Chair)	23,125	474,035	0	0	0	497,160
Gail MarcusIndependent · Audit Committee · Nominating, Corporate Governance and Compliance Committee (Chair)	21,875	470,145	0	0	0	492,020
Monica BertagnolliIndependent · Nominating, Corporate Governance and Compliance Committee · Newly elected	4,688	463,797	0	0	0	468,484
Ruth Williams-BrinkleyIndependent · Human Capital Committee	17,500	411,665	0	0	0	429,165
Roy BaynesIndependent · Nominating, Corporate Governance and Compliance Committee	17,840	409,620	0	0	0	427,459
James HealyIndependent · Audit Committee · Human Capital Committee	21,838	0	0	0	0	21,838
Matthew RabinowitzEmployee director · Board Chair	0	0	0	—	0	0
Steven ChapmanEmployee director	0	0	0	—	0	0
Jonathan SheenaNot independent	0	0	0	0	0	0

Board fee structure and ownership guideline

Annual cash retainer	$60,000
Annual equity retainer	$355,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	25,000 / 20,000 / 15,000
Stock ownership guideline	$180,000

Total cost of the board

Component	FY2025
Cash retainers and fees	$160,539
Equity awards (grant-date value)	$3,190,124
All other compensation	$0
Total cost of the board	$3,350,663

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Natera as a peer

Companies that benchmark against NTRA

24 companies name NTRA as a compensation peer

The list of companies that name NTRA as a peer is temporarily unavailable — recheck shortly.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

ALNY Alnylam Pharmaceuticals, Inc. BeiGeneBMRN BioMarin Pharmaceutical Inc.TECH Bio-Techne CorporationEXEL Exelixis, Inc.GH Guardant Health, Inc.ILMN Illumina, Inc.INCY Incyte Corp.IONS Ionis Pharmaceuticals, Inc.MASI Masimo CorporationNBIX Neurocrine Biosciences, Inc.QLYS Qualys, Inc.RGEN Repligen CorporationRVTY Revvity, Inc.SRPT Sarepta Therapeutics, Inc.UTHR United Therapeutics CorporationEXAS Exact Sciences CorporationPODD Insulet Corp.

Peer reciprocity

The companies Natera names as compensation peers that name it back in their own disclosed peer groups.

Bio-Techne Corporation (TECH)²⁵²Exelixis, Inc. (EXEL)²⁵³Guardant Health, Inc. (GH)²⁵⁴Repligen Corporation (RGEN)²⁵⁵Revvity, Inc. (RVTY)²⁵⁶Exact Sciences Corporation (EXAS)²⁵⁷

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Exelixis, Inc.	2025	Michael Morrissey	$1,306,040	$30,539,552	$0	$1,382,591	$33,239,183
2	Incyte Corp.	2025	William Meury	647,260	27,509,657	2,573,998	1,300,000	32,085,952
3	BioMarin Pharmaceutical Inc.	2025	Alexander Hardy	1,130,769	16,833,629	1,909,310	1,644,500	21,927,563
4	Masimo Corporation	2025	Catherine Szyman	850,048	16,388,693	1,399,998	1,130,000	19,797,140
5	Insulet Corp.	2025	Ashley McEvoy	729,808	12,958,850	2,999,913	2,031,562	18,858,968
6	United Therapeutics Corporation	2025	Martine Rothblatt	1,545,005	6,067,990	6,075,804	4,281,875	18,038,972
7	Qualys, Inc.	2025	Sumedh Thakar	616,167	14,597,565	0	723,377	15,947,158
8	Exact Sciences Corporation	2024	Kevin Conroy	1,083,368	13,496,138	0	712,329	15,539,378
9	Natera	2025	Steven Chapman	853,710	12,979,558	0	1,114,151	14,957,319
10	Alnylam Pharmaceuticals, Inc.	2025	Yvonne Greenstreet	1,404,200	5,512,500	4,363,380	3,562,500	14,867,600
11	Revvity, Inc.	2025	Prahlad R. Singh	1,129,231	7,694,985	2,559,152	2,385,450	13,809,549
12	Neurocrine Biosciences, Inc.	2025	Kyle Gano	920,000	5,750,023	5,750,006	0	13,448,935
13	Ionis Pharmaceuticals, Inc.	2025	Brett Monia	1,051,776	8,444,838	1,438,105	0	13,350,777
14	Illumina, Inc.	2025	Jacob Thaysen	1,000,000	8,763,122	0	1,155,000	11,018,895
15	Guardant Health, Inc.	2025	AmirAli Talasaz	1	8,647,709	0	0	8,661,227
16	Bio-Techne Corporation	2025	Kim Kelderman	936,000	3,929,942	1,932,848	1,318,917	8,151,181
17	Sarepta Therapeutics, Inc.	2025	Douglas Ingram	1,171,425	6,000,005	0	649,000	7,840,666
18	Repligen Corporation	2025	Olivier Loeillot	860,000	3,374,853	1,095,626	774,000	6,114,771

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Natera	131.1%	PSU 50 · RSU 50	No	Aon
Alnylam Pharmaceuticals, Inc.	200%	PSU 50 · RSU 25 · Option 25	No	Pay Governance
Bio-Techne Corporation	128.1%	PSU 50 · Options 25 · RSU 25	No	Aon
BioMarin Pharmaceutical Inc.	130%	PSU 66 · RSU 21 · Options 13	Yes — Relative TSR	Aon Human Capital Solutions
Exact Sciences Corporation	47%	PSU 60 · RSU 40	No	Aon
Exelixis, Inc.	105%	PSU 50 · RSU 50	Yes — 2025 Relative TSR Goal	Aon
Guardant Health, Inc.	140%	PSU 50 · RSU 50 · Option 35	No	Aon
Illumina, Inc.	not disclosed	not disclosed	Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index	Aon
Incyte Corp.	138.6%	Performance Shares 60 · RSU 40	Yes — relative total shareholder return (TSR)	Aon
Insulet Corp.	195.8%	PSU 60 · RSU 20 · Options 20	No	Pearl Meyer & Partners, LLC
Ionis Pharmaceuticals, Inc.	not disclosed	PRSU 40 · Option 30 · RSU 30	Yes — Relative TSR	Aon
Masimo Corporation	not disclosed	not disclosed	not disclosed	FW Cook
Neurocrine Biosciences, Inc.	105%	Option 50 · PRSU 30 · RSU 20	No	Frederic W. Cook & Co., Inc.
Qualys, Inc.	not disclosed	not disclosed	No	Compensia, Inc.
Repligen Corporation	100%	RSU 50 · PSU 25 · Options 25	No	Meridian Compensation Partners, LLC
Revvity, Inc.	124%	PSU 50 · RSU 25 · Options 25	No	Pearl Meyer
Sarepta Therapeutics, Inc.	100%	PSU 50 · Option 25 · RSU 25	No	FW Cook
United Therapeutics Corporation	221%	PSO 50 · PSU 50	No	Aon

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-06-11	119,883,700	2,492,978	343,875	97.96%	Passed
2025	2025-06-12	107,796,630	4,604,390	147,007	95.9%	Passed
2024	2024-06-12	101,567,539	5,854,068	60,358	94.55%	Passed
2023	2023-06-09	88,588,552	4,729,453	86,259	94.93%	Passed
2022	2022-05-25	39,574,100	36,870,671	66,564	51.77%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-06-11	97.96%^a
2025	2025-06-12	95.9%^b
2024	2024-06-12	94.55%^c

a. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of this proposal.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not affect the outcome of this proposal, other than counting towards the quorum of the meeting.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not affect the outcome of this proposal, other than counting towards the quorum of the meeting.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	101 : 1
CEO total compensation	$14,957,319
Median employee compensation	$148,726

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-01	D	1,400	$276	$386,740	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-01	D	500	274	137,095	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-07-01	D	300	274	82,218	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-07-01	D	2,600	273	709,774	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-07-01	D	100	267	26,719	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-01	D	2,045	277	567,056	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-01	D	1,100	275	302,717	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-01	D	454	272	123,551	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-01	D	484	270	130,616	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-01	D	1,357	271	367,699	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-01	D	1,932	269	519,694	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-01	D	1,955	278	543,973	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-07-06	D	1,000	280	280,000	Common	Form 4 ↗
Jonathan Sheena	Director	2026-07-13	D	500	267	133,377	Common	Form 4 ↗
Jonathan Sheena	Director	2026-07-13	D	500	268	134,194	Common	Form 4 ↗
Jonathan Sheena	Director	2026-07-13	D	450	268	120,475	Common	Form 4 ↗
Jonathan Sheena	Director	2026-07-13	D	400	265	106,060	Common	Form 4 ↗
Jonathan Sheena	Director	2026-07-13	D	800	264	211,436	Common	Form 4 ↗
Jonathan Sheena	Director	2026-07-13	D	500	263	131,358	Common	Form 4 ↗
Jonathan Sheena	Director	2026-07-15	D	100	274	27,368	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-07-15	D	80	276	22,081	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-07-15	D	40	276	11,055	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-07-15	D	170	275	46,795	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-07-15	D	450	273	122,871	Common, indirect	Form 4 ↗
Rowan E. Chapman	Director	2026-07-15	D	135	275	37,101	Common	Form 4 ↗
Jonathan Sheena	Director	2026-07-15	D	390	273	106,473	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-07-15	D	90	274	24,683	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-07-15	D	180	275	49,497	Common, indirect	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-07-27	D	782	260	203,704	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-07-27	D	2,190	260	570,475	Common	Form 4 ↗
John Fesko	President, Chief BUS. Officer	2026-07-27	D	782	260	203,704	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-07-27	D	1,010	260	263,096	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-07-27	D	1,718	260	447,523	Common	Form 4 ↗
Jonathan Sheena	Director	2026-07-27	D	288	260	75,021	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-27	D	884	260	230,274	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-07-28	D	1,008	254	255,797	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-07-28	D	3,580	254	909,572	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-07-28	D	1,204	254	305,901	Common	Form 4 ↗
Jonathan Sheena	Director	2026-07-28	D	191	254	48,527	Common	Form 4 ↗
John Fesko	President, Chief BUS. Officer	2026-07-28	D	931	254	236,540	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-07-28	D	1,003	254	254,833	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-07-28	D	170	254	43,237	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-07-28	D	1,241	254	315,301	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-07-29	D	1,863	249	464,595	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-08-03	D	676	264	178,371	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-08-03	D	200	261	52,298	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-03	D	109	268	29,211	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-08-03	D	731	268	195,900	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-08-03	D	334	268	89,508	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-08-03	D	947	264	249,953	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-08-03	D	410	268	109,876	Common	Form 4 ↗
John Fesko	President, Chief BUS. Officer	2026-08-03	D	295	268	79,057	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-08-03	D	612	268	164,150	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-08-03	D	80	265	21,222	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-08-03	D	70	261	18,272	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-08-03	D	160	260	41,597	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-08-03	D	1,182	268	316,763	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-08-03	D	317	268	84,953	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-08-03	D	1,233	268	330,181	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-08-03	D	296	267	79,057	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-08-03	D	192	265	50,933	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-08-03	D	128	269	34,393	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-08-03	D	300	260	77,994	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-08-04	D	478	274	131,077	Common	Form 4 ↗
John Fesko	President, Chief BUS. Officer	2026-08-06	A	20,000	0	0	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-07	D	200	318	63,593	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-07	D	100	319	31,863	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-07	D	5,111	317	1,618,203	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-07	D	600	315	189,191	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-07	D	850	314	267,114	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-07	D	900	313	281,760	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-07	D	400	312	124,752	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-07	D	400	310	124,090	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-07	D	100	308	30,840	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-07	D	489	321	156,920	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-08-07	D	2,000	321	641,800	Common	Form 4 ↗
John Fesko	President, Chief BUS. Officer	2026-08-10	D	6,517	322	2,095,411	Common	Form 4 ↗
Jonathan Sheena	Director	2026-08-10	D	6,000	325	1,951,942	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-09-01	D	1,698	321	545,041	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-09-01	D	600	322	193,144	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-09-01	D	1,000	320	319,758	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-09-01	D	1,400	321	449,292	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-09-02	D	15,160	327	4,955,713	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-11	D	17,933	328	5,881,529	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-11	D	3,647	326	1,189,315	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-11	D	1,300	330	428,512	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-11	D	15,764	329	5,185,571	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-11	D	800	325	260,006	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-11	D	10,556	327	3,453,334	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	2,700	341	921,636	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	2,100	339	712,673	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	4,064	343	1,391,947	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	2,000	340	680,626	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	1,400	338	473,614	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	2,207	337	744,132	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	8,459	336	2,844,474	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	2,818	334	941,878	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	1,000	332	332,017	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	6,206	330	2,048,299	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	1,537	328	504,281	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	2,246	333	748,065	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	3,494	331	1,156,427	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	3,754	335	1,258,268	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-14	D	6,015	329	1,979,639	Common	Form 4 ↗
Jonathan Sheena	Director	2026-09-15	D	6,000	350	2,100,431	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	14,500	351	5,086,700	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	2,000	350	700,014	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	800	351	280,996	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	4,206	350	1,470,038	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	8,094	349	2,821,945	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	2,700	348	939,094	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	2,700	345	932,525	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	5,839	344	2,011,453	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	1,956	342	669,305	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	1,813	341	618,970	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	1,481	339	502,407	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	1,122	347	388,969	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	2,240	344	769,583	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-09-15	D	2,549	340	867,293	Common	Form 4 ↗
Jonathan Sheena	Director	2026-09-16	D	200	357	71,373	Common	Form 4 ↗
Jonathan Sheena	Director	2026-09-16	D	800	356	284,758	Common	Form 4 ↗
Jonathan Sheena	Director	2026-09-16	D	450	355	159,711	Common	Form 4 ↗
Jonathan Sheena	Director	2026-09-16	D	1,400	354	495,362	Common	Form 4 ↗
Jonathan Sheena	Director	2026-09-16	D	100	349	34,905	Common	Form 4 ↗
Jonathan Sheena	Director	2026-09-16	D	200	348	69,605	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-09-16	D	945	0	0	Common	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	2,846	388	1,103,494	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	110	390	42,946	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	2,320	390	904,069	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	1,341	389	521,332	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	2,300	387	889,271	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	1,293	389	502,598	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	2,734	388	1,059,847	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	2,175	387	841,104	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	400	385	154,041	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	220	391	85,916	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	1,935	390	754,090	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-09-23	D	390	385	150,263	Common, indirect	Form 4 ↗
Steven Leonard Chapman	Director	2026-10-01	D	1,273	413	526,144	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-10-01	D	200	412	82,324	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-10-01	D	954	413	394,104	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-10-01	D	1,846	415	766,218	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-07	D	6,000	0	0	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	1,400	407	569,282	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	6,274	405	2,542,096	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	1,100	397	436,875	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	714	390	278,345	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	A	50,000	10	520,500	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	3,858	403	1,555,798	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	5,974	401	2,398,094	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	2,671	400	1,069,226	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	300	392	117,473	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	286	388	111,059	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	10,321	405	4,176,306	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	6,309	402	2,537,684	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	600	398	238,854	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	1,900	396	752,979	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	800	393	314,777	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	50,000	0	0	Derivative, Class A Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	2,000	408	816,471	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	3,800	407	1,547,612	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	793	399	316,655	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	300	394	118,319	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-15	D	600	390	234,123	Common	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	90	404	36,333	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	142	399	56,651	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	280	401	112,360	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	98	409	40,116	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	215	399	85,858	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	80	406	32,485	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	60	402	24,097	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	280	401	112,189	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	80	409	32,749	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	35	407	14,232	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	50	405	20,258	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-16	D	90	404	36,383	Common, indirect	Form 4 ↗
Jonathan Sheena	Director	2026-10-21	D	165	417	68,751	Common	Form 4 ↗
Jonathan Sheena	Director	2026-10-21	D	211	412	86,974	Common	Form 4 ↗
Jonathan Sheena	Director	2026-10-21	D	255	416	105,995	Common	Form 4 ↗
Jonathan Sheena	Director	2026-10-21	D	125	413	51,631	Common	Form 4 ↗
Jonathan Sheena	Director	2026-10-21	D	605	411	248,847	Common	Form 4 ↗
Jonathan Sheena	Director	2026-10-21	D	627	410	257,003	Common	Form 4 ↗
Jonathan Sheena	Director	2026-10-21	D	962	408	392,745	Common	Form 4 ↗
Jonathan Sheena	Director	2026-10-21	D	200	407	81,300	Common	Form 4 ↗
John Fesko	President, Chief BUS. Officer	2026-10-27	D	781	406	317,086	Common	Form 4 ↗
Jonathan Sheena	Director	2026-10-27	D	291	406	118,146	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-10-27	D	1,010	406	410,060	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-10-27	D	884	406	358,904	Common	Form 4 ↗
Matthew Rabinowitz	Director	2026-10-27	D	1,718	406	697,508	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-10-27	D	2,264	406	919,184	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-10-27	D	781	406	317,086	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-10-28	D	865	427	369,245	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-10-28	D	313	425	133,126	Common	Form 4 ↗
John Fesko	President, Chief BUS. Officer	2026-10-28	D	898	426	382,854	Common	Form 4 ↗
Jonathan Sheena	Director	2026-10-28	D	187	426	79,726	Common	Form 4 ↗
Solomon Moshkevich	President, Clinicaldiagnostics	2026-10-28	D	1,162	426	495,408	Common	Form 4 ↗
Matthew Rabinowitz	SEC. and Chief Legal Officer	2026-10-28	D	968	426	412,698	Common	Form 4 ↗
Steven Leonard Chapman	Director	2026-10-28	D	3,430	426	1,462,348	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-10-28	D	1,198	426	510,756	Common	Form 4 ↗
Michael Brophy	Chief Financial Officer	2026-10-30	D	1,906	426	811,098	Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (257 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Steven Chapman. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 59. As printed: 14,957,319. View filing ↗
Section 01, Matthew Rabinowitz. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 59. As printed: 11,283,382. View filing ↗
Section 01, Michael Brophy. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 59. As printed: 5,460,022. View filing ↗
Section 01, Solomon Moshkevich. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 59. As printed: 5,367,000. View filing ↗
Section 01, John Fesko. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 59. As printed: 5,052,790. View filing ↗
Section 03, Steven Chapman RSU. DEF 14A, filed 2026-04-23. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Steven Chapman PSU. DEF 14A, filed 2026-04-23. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Solomon Moshkevich RSU. DEF 14A, filed 2026-04-23. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Matthew Rabinowitz PSU. DEF 14A, filed 2026-04-23. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Michael Brophy PSU. DEF 14A, filed 2026-04-23. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, John Fesko PSU. DEF 14A, filed 2026-04-23. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Solomon Moshkevich PSU. DEF 14A, filed 2026-04-23. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, John Fesko RSU. DEF 14A, filed 2026-04-23. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Matthew Rabinowitz RSU. DEF 14A, filed 2026-04-23. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Michael Brophy RSU. DEF 14A, filed 2026-04-23. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2026-04-23. Section “CEO Pay Ratio”. As printed: 101 : 1. View filing ↗
Section 08, Roelof Botha. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 513,465. View filing ↗
Section 08, Herm Rosenman. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 501,070. View filing ↗
Section 08, Rowan Chapman. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 497,160. View filing ↗
Section 08, Gail Marcus. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 492,020. View filing ↗
Section 08, Monica Bertagnolli. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 468,484. View filing ↗
Section 08, Ruth Williams-Brinkley. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 429,165. View filing ↗
Section 08, Roy Baynes. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 427,459. View filing ↗
Section 08, James Healy. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 21,838. View filing ↗
Section 08, Matthew Rabinowitz. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
Section 08, Steven Chapman. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
Section 08, Jonathan Sheena. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-13. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-13. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-13. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-13. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-13. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-13. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Rowan E. Chapman 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-07-27. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-07-27. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Fesko 2026-07-27. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-07-27. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-27. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-27. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-27. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Fesko 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-07-29. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Fesko 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Fesko 2026-08-06. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-08-07. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Fesko 2026-08-10. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-08-10. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-11. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-09-23. Form 4, filed 2026-09-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-07. Form 4, filed 2026-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-16. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Fesko 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-10-28. Form 4, filed 2026-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-10-28. Form 4, filed 2026-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Fesko 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jonathan Sheena 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Solomon Moshkevich 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Matthew Rabinowitz 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Steven Leonard Chapman 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-10-28. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Brophy 2026-10-30. Form 4, filed 2026-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-06-16. Item 5.07 · say-on-pay result. As reported: 97.96% (votes for as printed: 119,883,700). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-06-18. Item 5.07 · say-on-pay result. As reported: 95.9% (votes for as printed: 107,796,630). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-06-18. Item 5.07 · say-on-pay result. As reported: 94.55% (votes for as printed: 101,567,539). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 160,539 + equity 3,190,124 + all other 0 = 3,350,663, summed across the director compensation table rows.
Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
Incyte Corp., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corp.'s own proxy. As printed: 32,085,952. View filing ↗
BioMarin Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. View filing ↗
Masimo Corporation, Section 10b CEO total. 10-K/A, filed 2026-05-01. CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 19,797,140. View filing ↗
Insulet Corp., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Insulet Corp.'s own proxy. As printed: 18,858,968. View filing ↗
United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
Qualys, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Qualys, Inc.'s own proxy. As printed: 15,947,158. View filing ↗
Exact Sciences Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. View filing ↗
Natera (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Natera's own proxy. As printed: 14,957,319. View filing ↗
Alnylam Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. View filing ↗
Revvity, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. View filing ↗
Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
Ionis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. View filing ↗
Illumina, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. View filing ↗
Guardant Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. View filing ↗
Bio-Techne Corporation, Section 10b CEO total. DEF 14A, filed 2025-09-19. CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. View filing ↗
Sarepta Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. View filing ↗
Repligen Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. View filing ↗
Section 10a, Bio-Techne Corporation reciprocity. DEF 14A. Bio-Techne Corporation names Natera in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Exelixis, Inc. reciprocity. DEF 14A. Exelixis, Inc. names Natera in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Guardant Health, Inc. reciprocity. DEF 14A. Guardant Health, Inc. names Natera in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Repligen Corporation reciprocity. DEF 14A. Repligen Corporation names Natera in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Revvity, Inc. reciprocity. DEF 14A. Revvity, Inc. names Natera in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Exact Sciences Corporation reciprocity. DEF 14A. Exact Sciences Corporation names Natera in its own disclosed peer group (read from its most recent proxy). View filing ↗